Evaluation of the effect of calcitriol supplementation on diabetes control and its complications in hyperlipidemic patients with type 2 diabetes mellitus, Shiraz, 2009

Evaluation of the effect of calcitriol supplementation on glucose, insulin, hemoglobin A1C, lipid profile and oxidative stress markers in hyperlipidemic patients with type 2 diabetes mellitus, Shiraz, 2009

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT138806282480N1

Enrollment

Registered

2010-05-08

Start date

2009-08-01

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes mellitus. Non-insulin-dependent diabetes mellitus

Interventions

Intervention 1: calcitriol intake, 0.5 mcg per day, for 3 months. Intervention 2: placebo intake for 3 months.

Placebo

Treatment - Drugs

calcitriol intake, 0.5 mcg per day, for 3 months

placebo intake for 3 months

Eligibility

Sex/Gender

All

Age

30 Years to No maximum

Inclusion criteria

Inclusion criteria: Inclusion criteria: Age>30 years, Hb.A1C<8%, FBS<160 mg/dl, Serum Calcium < 10.5 mg/dl, LDL<150 mg/dl, normal liver and kidney function, no history of kidney stone, not taking insulin therapy, no hypercalcemia was seen. Exclusion criteria: using vitamin D supplement, pregnancy, smoking, UVB exposure with therapeutic goals, acute kidney or liver disease, hypercalcemia, hyperparathyroidism.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
FBS. Timepoint: 3 times, with 1.5 month intervals. Method of measurement: Auto analyser.;Serum insulin. Timepoint: 3 times, with 1.5 month intervals. Method of measurement: with Eliza kit, Monobind.	—

Secondary

Measure	Time frame
Hb.A1C. Timepoint: before and after intervention. Method of measurement: Nycocard kit.;MDA (Malondialdehyde). Timepoint: before and after intervention. Method of measurement: spectrophotometery.;Lipid profile. Timepoint: 3 times, with 1.5 month intervals. Method of measurement: auto analysor.;Interleukin 1. Timepoint: 2 times with 3 month intervals. Method of measurement: eliza kit.;Interleukin 6. Timepoint: 2 times with 3 month intervals. Method of measurement: eliza kit.;Interleukin 18. Timepoint: 2 times with 3 month intervals. Method of measurement: eliza kit.;CRP. Timepoint: 2 times with 3 month intervals. Method of measurement: eliza kit.	—

Measure

Time frame

Hb.A1C. Timepoint: before and after intervention. Method of measurement: Nycocard kit.;MDA (Malondialdehyde). Timepoint: before and after intervention. Method of measurement: spectrophotometery.;Lipid profile. Timepoint: 3 times, with 1.5 month intervals. Method of measurement: auto analysor.;Interleukin 1. Timepoint: 2 times with 3 month intervals. Method of measurement: eliza kit.;Interleukin 6. Timepoint: 2 times with 3 month intervals. Method of measurement: eliza kit.;Interleukin 18. Timepoint: 2 times with 3 month intervals. Method of measurement: eliza kit.;CRP. Timepoint: 2 times with 3 month intervals. Method of measurement: eliza kit.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMarzieh Akbarzadeh

School of health and nutrition, Shiraz University of Mediccal Sciences

marzieh_akbarzadeh@yahoo.com+98 71 1725 1001

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026